MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.26
-0.10
-0.58%
After Hours: 17.69 +0.43 +2.49% 18:50 09/17 EDT
OPEN
17.19
PREV CLOSE
17.36
HIGH
17.67
LOW
17.05
VOLUME
67.14K
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
6.17
MARKET CAP
84.47M
P/E (TTM)
-2.2956
1D
5D
1M
3M
1Y
5Y
Aptevo Therapeutics Reports APVO436 Monotherapy Is Active In Patients Who Have Relapsed Acute Myeloid Leukemia Or Myelodysplastic Syndrome
Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was published in the
Benzinga · 08/17 12:08
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapiesData was published in the prestigious oncology journal Cancers
ACCESSWIRE · 08/17 12:05
BRIEF-Aptevo Therapeutics Inc Files Prospectus Related To Resale Of Up To 1,250,000 Shares Of The Common Stock
reuters.com · 08/12 21:39
Aptevo Therapeutics Q2 EPS $(1.75) Up From $(2.10) YoY
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(1.75) per share. This is a 16.67 percent increase over losses of $(2.10) per share from the same period last year.
Benzinga · 08/12 12:29
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported it...
ACCESSWIRE · 08/12 12:06
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 07/16 16:39
China SXT Pharmaceuticals, Trinity Biotech leads healthcare gainers; FibroGen, Neptune Wellness Solutions among major losers
Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutics (ATOS) -16%...
Seekingalpha · 07/16 15:01
Aptevo Therapeutics Chief Scientific Officer Jane Gross, To Present At Upcoming Cambridge Health Institute PEGS Virtual Conference Jul. 19-22
Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™
Benzinga · 07/16 12:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APVO stock price target is 59.50 with a high estimate of 69.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 5.52M
% Owned: 112.70%
Shares Outstanding: 4.89M
TypeInstitutionsShares
Increased
9
84.59K
New
6
216.02K
Decreased
6
110.60K
Sold Out
11
212.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About APVO
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multi-specific antibody candidates that are capable for the human immune system against cancer cells. The Company's lead product candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using the ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using the ADAPTIR-FLEX modular protein technology platform. APVO436 is a recombinant, bispecific T-cell engaging antibody candidate that is designed to target CD123, CD3 and redirect T-cell cytotoxicity to the tumor.

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.